motexafin lutetium
Small moleculeexperimental
Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc. — Wikipedia
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2000 (NCT00005067)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMotexafin lutetium ↗
Also known as
- lutetium texaphyrin
- lutex
- lu-tex
- lutrin
- lutrin
- motexafin lutetium
- motexafin lutetium
- motexafin lutetium
- motexafin lutetium
- optrin
- pci 0123
- pci-0123
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00087191 | N/A | May 1, 2004 | National Cancer Institute (NCI), University of Pennsylvania |
| NCT00005808 | Phase 1 | Dec 1, 2000 | National Cancer Institute (NCI), University of Pittsburgh |
| NCT00005067 | Phase 1 | Feb 1, 2000 | National Cancer Institute (NCI), University of Pennsylvania |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 3 | 2 | 2000 |
| University of Pennsylvania | Academic/Hospital | 2 | 0 | 2 | 2000 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2000 |
3 organizations
Page 1 / 1